

Biallelic variants for autism....

1 **Autism spectrum disorder trios from consanguineous populations are enriched**  
2 **for rare biallelic variants, identifying 32 new candidate genes**

3 **Running title:** Biallelic variants for autism and consanguinity

4

5 Ricardo Harripaul<sup>1,2§</sup>, Ansa Rabia<sup>1,3,4§</sup>, Nasim Vasli<sup>1</sup>, Anna Mikhailov<sup>1</sup>, Ashlyn Rodrigues<sup>1</sup>,  
6 Stephen F. Pastore<sup>1</sup>, Tahir Muhammad<sup>1,2</sup>, Thulasi Thiruvallur Madanagopal<sup>1</sup>, Aisha Nasir  
7 Hashmi<sup>1</sup>, Clinton Tran<sup>1</sup>, Cassandra Stan<sup>1</sup>, Katherine Aw<sup>1</sup>, Clement Zai<sup>1</sup>, Maleeha Azam<sup>5</sup>, Saqib  
8 Mahmood<sup>3</sup>, Abolfazl Heidari<sup>6</sup>, Raheel Qamar<sup>5,7</sup>, Leon French<sup>2,8</sup>, Shreejoy Tripathy<sup>2,8</sup>, Zehra  
9 Agha<sup>5,9</sup>, Muhammad Iqbal<sup>10</sup>, Majid Ghadami<sup>11</sup>, Susan L. Santangelo<sup>12,13</sup>, Bita Bozorgmehr<sup>1</sup>, Laila  
10 Al Ayadhi<sup>14</sup>, Roksana Sasanfar<sup>15,16</sup>, Shazia Maqbool<sup>17</sup>, James A. Knowles<sup>18</sup>, Muhammad  
11 Ayub<sup>19,20\*</sup>, John B Vincent<sup>1,2,21\*</sup>

12

13 <sup>1</sup>Molecular Neuropsychiatry & Development (MiND) Lab, Campbell Family Mental Health

14 Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada;

15 <sup>2</sup>Institute of Medical Science, University of Toronto, Toronto, ON, Canada;

16 <sup>3</sup>University of Health Sciences, Lahore, Pakistan;

17 <sup>4</sup>CMH Lahore Medical College & Institute of Dentistry, Lahore (affiliated with National

18 University of Medical Sciences, Rawalpindi), Pakistan;

19 <sup>5</sup>Department of Biosciences, COMSATS University Islamabad, Islamabad, Pakistan;

## Biallelic variants for autism....

- 20 <sup>6</sup>Sana Medical Genetics Laboratory, Qazvin, Iran; Reference Laboratory of Qazvin Medical  
21 University, Qazvin, Iran;
- 22 <sup>7</sup>Science and Environment Sector, ICESCO, Rabat, Kingdom of Morocco;
- 23 <sup>8</sup>Krembil Centre for Neuroinformatics, Centre for Addiction and Mental Health, Toronto, ON,  
24 Canada;
- 25 <sup>9</sup>Department of Psychiatry, State University of New York at Buffalo; Jacobs School of Medicine  
26 and Biomedical Sciences, Buffalo, NY, USA;
- 27 <sup>10</sup>Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia;
- 28 <sup>11</sup>Department of Educational Sciences, Farhangian University, Tehran, Iran;
- 29 <sup>12</sup>Center for Clinical and Translational Research, Maine Health Institute for Research,  
30 Scarborough ME, 04074, USA;
- 31 <sup>13</sup>Tufts University School of Medicine, Boston, MA, 02110, USA;
- 32 <sup>14</sup>Autism Research & Treatment Center, Department of Physiology, Faculty of Medicine,  
33 National Plan for Science and Technology (NPST), King Saud University, Riyadh, Saudi Arabia;
- 34 <sup>15</sup>Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetic Research,  
35 Massachusetts General Hospital, Boston, MA 02114, USA;
- 36 <sup>16</sup>Department of Psychiatry, Harvard Medical School, Boston, MA, USA;
- 37 <sup>17</sup>The University of Child Health Sciences, Children's Hospital, Lahore, Pakistan;
- 38 <sup>18</sup>Human Genetics Institute of New Jersey and Department of Genetics, Rutgers University,  
39 Piscataway, NJ, USA;
- <sup>19</sup>Department of Psychiatry, Queens University Kingston, Kingston, ON, Canada;

Biallelic variants for autism....

<sup>20</sup>Division of Psychiatry, University College London, London, UK;

40 <sup>21</sup>Department of Psychiatry, University of Toronto, Toronto, ON, Canada.

41 §Equal contribution

42 \*Correspondence should be addressed to:

43 Dr. John B. Vincent, Brain Molecular Science, Campbell Family Mental Health Research Institute,

44 Centre for Addiction and Mental Health (CAMH), 250 College Street, Toronto, ON, Canada, M5T

45 1R8; Email: [john.vincent@camh.ca](mailto:john.vincent@camh.ca)

46 Dr. Muhammad Ayub, Division of Psychiatry, University College London, 149 Tottenham Ct Rd,

47 London W1T 7NF, United Kingdom. Email: [m.ayub@ucl.ac.uk](mailto:m.ayub@ucl.ac.uk)

48

Biallelic variants for autism....

49 **Abstract**

50 **Background:** Autism spectrum disorder (ASD) is a neurodevelopmental disorder that affects  
51 about 1 in 36 children in the United States, imposing enormous economic and socioemotional  
52 burden on families and communities. Genetic studies of ASD have identified *de novo* copy  
53 number variants (CNVs) and point mutations that contribute significantly to the genetic  
54 architecture, but the majority of these studies were conducted in populations unsuited for  
55 detecting autosomal recessive (AR) inheritance. However, several ASD studies in  
56 consanguineous populations point towards AR as an under-appreciated source of ASD variants.

57 **Methods:** We used whole exome sequencing to look for rare variants for ASD in 115 proband-  
58 mother-father trios from populations with high rates of consanguinity, namely Pakistan, Iran,  
59 and Saudi Arabia. Consanguinity was assessed through microarray genotyping.

60 **Results:** We report 84 candidate disease-predisposing single nucleotide variants and indels,  
61 with 58% biallelic, 25% autosomal dominant/*de novo*, and the rest X-linked, in 39 trios. 52% of  
62 the variants were loss of function (LoF) or putative LoF (pLoF), and 47% nonsynonymous. We  
63 found an enrichment of biallelic variants, both in sixteen genes previously reported for AR ASD  
64 and/or intellectual disability (ID) and 32 previously unreported AR candidate genes (including  
65 *DAGLA*, *ENPP6*, *FAXDC2*, *ILDR2*, *KSR2*, *PKD1L1*, *SCN10A*, *SHH*, and *SLC36A1*). We also identified  
66 eight candidate biallelic exonic loss CNVs.

67 **Conclusions:** The significant enrichment for biallelic variants among individuals with high  $F_{roh}$   
68 coefficients, compared with low  $F_{roh}$ , either in known or candidate AR genes, confirms that

## Biallelic variants for autism....

69 genetic architecture for ASD among consanguineous populations is different to non-  
70 consanguineous populations. Assessment of consanguinity may assist in the genetic diagnostic  
71 process for ASD.

72 **Keywords:** Autism spectrum disorder; Trio; Autosomal recessive; Consanguinity; Biallelic;  
73 Candidate Genes

74

75

Biallelic variants for autism....

## 76 **Introduction**

77 Autism spectrum disorder (ASD) is characterized by deficits in social communication,  
78 repetitive/restricted behaviours and interests. Apart from a small percentage of individuals who  
79 recover (1), ASD is a life-long condition and only about 20% have good outcomes, as reported in  
80 a recent meta-analysis of longitudinal studies (2). Phenotypically, individuals with ASD are  
81 heterogeneous in their level of intellectual functioning, and co-morbid psychiatric and  
82 behavioural problems. These factors play an important role in the long term end points of the  
83 disease (3). In a systematic review the prevalence of ASD was estimated to be 0.76%  
84 internationally (4). In another systematic review of international data, the median estimate was  
85 62/10,000 (5). In this review, the ASD prevalence showed little variation by geographic region,  
86 ethnic, cultural and socioeconomic factors (5).

87 The reported prevalence of ASD has increased with time. In the 1960s it was estimated  
88 to affect as few as 1 in 10,000 individuals (5), prevalence studies from the 1980s suggested that  
89 as many as 72 in 10,000 individuals had ASD, rising to 1% in the 2000s (5,6). More recent  
90 studies report prevalence rates of more than 2%. (7–9). In the United States the prevalence  
91 across eleven sites in 2016 was 18.5 per 1,000 (one in 54) children (10) and increasing to one in  
92 36 in the most recent report (11). This increase is partly due to changes in diagnostic criteria,  
93 reporting practices, and increased awareness (12–15).

94 A systematic review of literature from South Asian countries reported a prevalence of ASD  
95 in the range of 0.09-1.07 % (16). To date, there has been no community study of ASD prevalence  
96 in Pakistan. Studies from child psychiatry clinics reported rates of 2.4% and 3.2%, 4.5%, 5% (17–

## Biallelic variants for autism....

97 20). Clinical services and special schools for ASD are available in Pakistan, but are typically limited  
98 to major cities (21). The literature on clinical presentation is limited. One study with a small  
99 sample size shows symptoms consistent with studies elsewhere in the world (22).

100 Consanguineous marriages lead to a marked increase in the frequency of rare recessive  
101 disorders (23,24). Many genetic variants will only be pathogenic in recessive form; this includes  
102 variants for ID, and almost certainly for ASD too. Populations with a high proportion of  
103 consanguinity have been important for describing autosomal recessive genes in ID in Pakistan  
104 (25,26), Iran (27,28), Syria (29), and Saudi Arabia (30), yet, to date, relatively few reports of AR  
105 genes underlying ASD in consanguineous populations have been published (31–33). Previous  
106 work has highlighted recessive inheritance as an important component of the genetic  
107 architecture of ASD. For instance, a large study of consanguineous versus non-consanguineous  
108 families in India concluded that consanguinity increases the risk for ASD with an odds ratio of  
109 3.22 (34). Morrow and colleagues used SNP microarrays to map homozygous loci in 104 small  
110 ASD families from the Middle East, Turkey and Pakistan, finding homozygous deletions  
111 implicating *SLC9A9*, *PCDH10*, *CNTN3* and others (31).

112 Research in outbred populations also supports AR inheritance as an important piece of  
113 the genetic puzzle for ASD. For example, it has been estimated that loss-of-function (LoF)  
114 recessive mutations contribute 3% of ASD genetics in two US-based case-control cohorts (35).  
115 These findings are not limited to population isolates or ethnic subgroups (36,37). Identification  
116 of recessive genes in outbred populations is problematic, as the analysis pipelines for WES/WGS  
117 data are non-optimal for discovering compound heterozygous mutations.

## Biallelic variants for autism....

118           Despite the higher prevalence of recessive inheritance in consanguineous populations,  
119   data from studies of developmental disorder (DD) suggest that *de novo* variants are also  
120   prominent, albeit in a lower proportion e.g. in a UK study of 6040 families from the Deciphering  
121   Developmental Disorders (DDD) study, individuals of Pakistani ancestry had 29.8% *de novo*  
122   compared with 49.9% in the European ancestry UK population (38). In an Iranian ID study, the  
123   *de novo* rate was 27.86% (39).

124           Describing the genetic architecture of ASD is an important step towards  
125   understanding the pathogenesis of the disorder. There has been significant progress to date,  
126   and studies of ASD have shown that *de novo* copy number variants (CNVs) and point mutations  
127   play a prominent role, however, the majority of these studies have been conducted in outbred  
128   populations (40). Here, we report on a study of 84 genetic and 11 genomic variants (eight  
129   homozygous; 3 heterozygous) from a cohort of 115 ASD trios from three countries with a high  
130   frequency of consanguineous marriages (Pakistan, Iran, and Saudi Arabia).

## 131   **Materials and Methods**

### 132   **Trio Family Ascertainment**

133   Institutional Research Ethics Board approval was received from the Centre for Addiction and  
134   Mental Health (CAMH) and the recruitment sites. A summary of the cohorts, collaborator  
135   contributions, ascertainment, and assessment tools, is in Table 1. Overall, we have collected  
136   DNA from 115 trios: 62 trios from Pakistan, 40 trios from Iran, and 13 trios from Saudi Arabia,  
137   comprised of 345 individuals.



Biallelic variants for autism....

## 138 **Whole Exome Sequencing, Alignment and Variant Calling**

139 Whole Exome Sequencing (WES) was performed on all samples using the ThruPLEX DNA-Seq  
140 (Rubicon Genomics) Library Preparation Kit with the Agilent SureSelect V5 Exome Capture kit.  
141 DNA was sheared using a Covaris ME220 Focused-Sonicator 200 bp, which was verified using a  
142 Agilent 2100 Bioanalyzer System for fragment length distribution and quantification. All trios  
143 were sequenced on Illumina HiSeq 2500 or NovaSeq sequencing systems. Details of read QC,  
144 alignment, variant calling and prioritization are provided in Supplementary Materials, and  
145 summarized in Figure 1. Fifteen trios were previously run using the Ion Proton platform/Ion  
146 Ampliseq™ Exome kit (Life Technologies)- all were re-run using the Illumina platform except trio  
147 IABB3, for which a causative frameshifting deletion was detected in the VPS13B/Cohen  
148 syndrome gene.

## 149 **Microarray genotyping and analysis.**

150 Microarrays were run using DNA from 104 of the 115 ASD probands (where sufficient DNA was  
151 available), including 13 using Affymetrix CytoScanHD, 87 using Illumina CoreExome, and four  
152 with both arrays. CoreExome data in PLINK format was used for runs-of-homozygosity (RoH)  
153 analysis, using PLINK 1.9 (<http://pngu.mgh.harvard.edu/purcell/plink>). RoH data was used to  
154 generate an F-coefficient of consanguinity for the probands (and affected siblings),  $F_{\text{RoH}}$ , as  
155 described in McQuillan et al, 2008 (41), where  $F_{\text{roh}} = \sum L_{\text{roh}}/L_{\text{auto}}$ . Autosome size  $L_{\text{auto}}$  was  
156 estimated at 2,673,768 Kb. The CytoScanHD data was analysed using Chromosome Analysis  
157 Suite (ChAS), and a loss of heterozygosity (LoH) score was generated. For four samples that  
158 were run on both Illumina CoreExome and Affymetrix CytoScanHD arrays (probands from trios

Biallelic variants for autism....

159 IABB2, IABB3, IABB4, and IABB5), we were able to generate both  $F_{roh}$  and LoH scores, which, as  
160 the relationship was almost linear (Pearson  $R^2 = 0.9971$ ) allowed us to convert LoH scores from  
161 CytoScanHD microarrays to  $F_{roh}$  (Supplementary Materials). Comparison statistics were  
162 performed using GraphPad (<https://www.graphpad.com/>).

### 163 **Copy Number Variant (CNV) analysis**

164 CNV analysis of the CytoScanHD array data was performed using ChAS and PennCNV; for  
165 CoreExome data by the Illumina Genome Suite/CNVpartition and PennCNV. Evidence of  
166 homozygous loss CNVs was cross-references with WES data, using the Integrated Genome  
167 Viewer v2.3.5 (IGV: <https://software.broadinstitute.org/software/igv/>; (42), and CNVs  
168 corroborated in this manner were then checked by PCR. Further  
169 analysis/prioritization/validation of CNVs, including using WES data, is given in Supplementary  
170 Materials.

### 171 **Cross-referencing with other datasets**

172 In order to evaluate the strength of candidacy of the variants/genes identified here or to find  
173 supporting evidence, we cross-referenced our findings with other datasets listed below. We  
174 identified rare variants in the candidate genes we report here (Tables 2-4) that were either: 1.  
175 *De novo*, 2. Heterozygous LoF but status either *de novo* or unknown; 3. Biallelic (i.e.  
176 homozygous); 4. Putative biallelic (possibly compound heterozygous, but phasing unknown); 5.  
177 X-linked in males, maternally inherited. Data are shown in Supplementary File 1.

Biallelic variants for autism....

178 **MSSNG:** More than 13,000 individuals from the Autism Genetic Research Exchange (AGRE)  
179 repository and other cohorts have been whole-genome sequenced, through Autism Speaks, and  
180 data made available through the MSSNG database (<https://research.mss.ng>; db7 (43)). MSSNG  
181 data was accessed in May 2024.

182 **SFARI: SSC biallelic:** The Simons Simplex Collection (SSC) includes 2,600 simplex autism or  
183 related developmental disorder families. WES data is available for ~2,500 of these families,  
184 biallelic variants for our gene list were searched using the GPF browser  
185 (<https://gpf.sfari.org/gpf19/datasets/SSC/browser>). Putative compound heterozygous variants  
186 criteria for minor allele frequency (MAF) in SSC exome, gnomAD exome and genome  
187 frequencies, of <0.001, or, for missense variants, MCP scores >1 and CADD scores >18. **SVIP**  
188 **biallelic:** the autism Simons Variation in Individuals Project (SVIP) dataset was searched for  
189 putative biallelic variants through the browser [gpf.sfari.org/gpf19/datasets/SVIP/browser](https://gpf.sfari.org/gpf19/datasets/SVIP/browser).  
190 Putative compound heterozygous variants checked for criteria including minor allele frequency  
191 (MAF) in SSC exome, gnomAD exome and genome frequencies, of <0.001, or, for missense  
192 variants, MCP scores >1 and CADD scores >18.

193 **Deciphering Developmental Disorders (DDD) study:** includes sequence data for ~14,000  
194 children; this dataset was searched for variants in genes overlapping with our study through the  
195 known developmental genes list (<https://decipher.sanger.ac.uk/ddd#ddgenes>), as well as the  
196 list of research variants (<https://decipher.sanger.ac.uk/ddd#research-variants>), which are 2,723  
197 variants of unknown significance from 4,293 children. For *de novo* variants, all are constitutive,  
198 unless specifically noted as mosaic here. CNV variants are not included here.

Biallelic variants for autism....

199 **Autism Sequencing Consortium (ASC):** genes with *de novo* variants, either in the control set or  
200 case set, from ASC exome analysis browser (<https://asc.broadinstitute.org/>). This dataset lists  
201 numbers of *de novo* protein-truncating variants, as well as *de novo* missense variants with MCP  
202 scores either 1-2 or  $\geq 2$ . The ASC dataset includes 6,430 probands, and includes the SSC data.

203 **DeRubeis:** genes with *de novo* variants reported in the DeRubeis et al, 2014 study, with either  
204 LoF or missense variants (44). As subject IDs were not reported, overlap with other studies  
205 recorded here is not possible.

206 **AutismKB:** additional studies where variants have been reported for the genes are taken from  
207 the Autism Knowledge Base ([http://db.cbi.pku.edu.cn/autismkb\\_v2/quick\\_search.php](http://db.cbi.pku.edu.cn/autismkb_v2/quick_search.php)), (45).

#### 208 **Neuroanatomical Enrichment Analysis**

209 The Allen Adult Human Brain Atlas (46), Brainspan (47), and a single-cell atlas of the mouse  
210 nervous system (48) were used to test for neuroanatomically specific expression. For each  
211 gene, expression was standardized across regions or cell types. For these compartments, each  
212 gene was then ranked from most specific to most depleted. The area under the receiver  
213 operating statistic (AUC) was used to quantify specific expression for the genes of interest  
214 within a region or cell cluster. The Mann-Whitney U test was used to test statistical significance,  
215 and the Benjamini–Hochberg procedure (49) was used to correct for multiple tests. In addition,  
216 in order to explore whether our candidate genes may contribute to electrophysiological and  
217 morphological phenotypes in neurons we cross-referenced gene expression correlates with  
218 electrophysiological phenotypes through a dataset published by Bomkamp et al, 2019 (50).

219

Biallelic variants for autism....

## 220 Results

221 We ascertained, phenotyped, collect blood and/or saliva for DNA extraction, and performed  
222 whole exome sequencing (mean depth: 27.29; average % coverage at 30X=31.01; average %  
223 coverage at 100X=7.32; see Supplementary File 1) from 115 ASD proband  
224 (91M:24F)/mother/father trios (62 from Pakistan, 40 from Iran, and 13 from Saudi Arabia), for a  
225 total of 345 subjects (Table1). In addition, microarrays were run on 104 of the ASD probands,  
226 providing data for CNV and ROH analyses.

227 **Whole Exome Sequencing:** We discovered 84 SNVs or indels through our analysis pipeline,  
228 including 49 homozygous autosomal variants, 20 autosomal *de novo* (and 1 inherited) variants,  
229 and 5 *de novo* and 9 maternally inherited X-linked variants.

230 **Biallelic mutations (Table 2):** We identified homozygous variants (7 LoF or pLoF; 9  
231 nonsynonymous; 1 in-frame del) in 17 genes that have been previously reported to be  
232 associated with autosomal recessive non-syndromic ID, including *BTN3A2* (30), *CC2D1A* (MIM  
233 608443; MRT3; (51)), *LINS1* (28), *MADD* (30), *MTHFR* (29), *RSRC1* (52,53), *TECPR2* (30) and  
234 *ZNF335* (27), or for syndromic or metabolic forms of autosomal recessive ID, including *AGA*  
235 (aspartylglucosaminuria), *ASL* (arginosuccinic aciduria), *ASPA* (aspartoacylase  
236 deficiency/Canavan disease), and *HTRA2* (3-methylglutaconic aciduria). Three genes, *CC2D1A*,  
237 *DEAF1*, and *VPS13B* have also previously been associated with ASD or autistic features (94–96;  
238 (57)). Biallelic mutations in *DEAF1* are known to cause neurodevelopmental disorder with  
239 hypotonia, impaired expressive language, with or without seizures (MIM 617171). LoF variants  
240 were reported for new candidate genes *ENPEP*, *DAGLA*, *FAXDC2*, *GIMAP8*, *HRNR*, *ILDR2*,

## Biallelic variants for autism....

241 *SLC36A1*, *SCN10A*, *VPS16*, *ZNF766*, and pLoF (such as canonical splice site variants) in *CNPY4*,  
242 *DENND1B*, *LRRC34*, *PKD1L1*, and *PPP1R36*. *VPS16* has previously been reported for autosomal  
243 dominant dystonia (MIM 608559), and *PKD1L1* for AR visceral heterotaxy 8 (MIM 617205).  
244 Heterozygous missense and LoF mutations in *SHH* are known to be involved in autosomal  
245 dominant holoprosencephaly 3 (HPE3; MIM 142945), and so it is somewhat surprising to find a  
246 homozygous missense variant associated with a milder phenotype and with no obvious HPE3-  
247 related dysmorphic features. The Asn69Ile variant in *SHH* substitutes an asparagine for  
248 isoleucine at a residue that is conserved across vertebrates, is predicted to be damaging, and is  
249 found in heterozygous form in only 21 out of 1.6E6 gnomAD (v4.1.0) alleles, and no  
250 homozygotes.

251 In one trio (trio SMPA21) we report a homozygous stop-gain variant in *DAGLA*, for which  
252 rare heterozygous variants were reported to be associated with neurodevelopmental disorders,  
253 including autism (58). SFARI also lists this as a strong candidate for a ASD disease gene (gene  
254 score of 2; <https://gene.sfari.org/>). We also report homozygous missense variants in novel  
255 candidate genes *ANO10*, *CABP2*, *CAPSL*, *CLCA4*, *CPM*, *DNAH8*, *ERMP1*, *KSR2*, *RANBP9*, *RASAL2*,  
256 *TMEM25*, *TRIM3*, *VPS16*, and *WDR90*, plus in *SGSM3* and *EPHB1*, for which *de novo* variants in  
257 have been reported for ASD (59), and are listed respectively as strong candidate and suggestive  
258 evidence in SFARI (scores of 2 and 3, respectively).

259 Although not focused on consanguineous populations, WGS data from the MSSNG  
260 study, as well as WES studies such as DDD and SFARI, support a number of our candidate AR  
261 genes (see Supplementary File 1), with homozygous rare variants in *DNAH7* (MSSNG), *DNAH8*

## Biallelic variants for autism....

262 (MSSNG), *CAPSL* (MSSNG), and *CYP2A7* (MSSNG), and putative compound heterozygous  
263 damaging rare variants in *DNAH8* (in three MSSNG individuals), *SCN10A* (DDD), and *WDR90*  
264 (DDD)(see Supplementary File 1). There was also evidence of disease-causing biallelic variants  
265 in known AR neurodevelopmental genes *MTHFR* (three homozygous; DDD), *AGA* (one  
266 homozygous stop gain; DDD), *DEAF1* (two homozygous stop gain; MSSNG and DDD), *ZNF335*  
267 (one homozygous missense, DDD; one putative compound heterozygous, DDD), *ASL* (one  
268 homozygous missense; MSSNG), *CC2D1A* (one homozygous missense, MSSNG; two  
269 homozygous LoF DDD), and *VPS13B* (six homozygous, nine putative compound heterozygous).

270 ***De novo* mutations (Table 3 & 4):** *De novo* dominant mutations have been shown to be a major  
271 causal factor in ASD etiology. We identified 25 *de novo* variants (20 autosomal and 5 X-linked).  
272 Among these genes, variants in four of them have been identified in previous studies (*MECP2*,  
273 *MYT1L*, *SCN2A*, *ZNF292*). 14 of the 25 variants were LoF, three were putative LoF (splice site),  
274 and the remainder were nonsynonymous. The mutations include genes that have been  
275 implicated in other recent studies of ASD and/or ID. For instance, we report a *de novo*  
276 hemizygous nonsynonymous mutation in *CLTRN* (on chromosome X). Hemizygous mutations in  
277 *CLTRN* have recently been reported in several males with neutral aminoaciduria accompanied  
278 with autistic features, anxiety, depression, compulsions and motor tics (60)- a clinical picture  
279 reminiscent of the autosomal recessive Hartnup disorder (MIM 234500). There were also  
280 several other genes with *de novo* variants that have not been associated with ASD (or ID)  
281 previously, and may represent novel putative genes for ASD, and for other trios there are

## Biallelic variants for autism....

282 variants in genes linked with other nervous system disorders, such as *DRP2* in Charcot-Marie-  
283 Tooth disease (61).

284 Our study identified a *de novo* LoF mutation in *ZNF292* (NM\_015021:c.6159\_6160del;  
285 p.Glu2054Lysfs\*14) in two trios (IAU-65 (Iranian) and Autism-10 (Pakistani)). These two trios  
286 and 26 additional families (from multiple studies and cohorts) with mutations in *ZNF292* were  
287 reported recently (62).

288 Cross-referencing with other datasets, there was also support for new candidate  
289 dominant/*de novo* autosomal genes, including *ECM1*, *SLAMF7*, *NCL*, *FAM53C*, *ADGRF2*,  
290 *TANGO2*, *DGKZ*, *ATP2B1* (5 individuals), *CBFA2T3*, *RETN*, and *PPIL2* (see Supplementary File 1).  
291 There was support for X-linked recessive (in males, maternally inherited or *de novo*) candidate  
292 gene *NRK* (three individuals), *MAGEB2* (three individuals), *MAGEC1* (11 individuals), *MSN* (five  
293 individuals), and *ZNF185* (one individuals).

294

295 **X-linked (inherited; Table 4):** Two mutations were identified in well-established ASD or ID  
296 genes, namely, *AIFM1* (Cowchock syndrome; MIM 310490), and *MID2* (XLID101: MIM 300928).

## 297 **Splice site variants**

298 In addition to the detection of variants at canonical splice donor and splice acceptor sites  
299 (Tables 2-4), use of SpliceAI suggests that, for the biallelic nonsynonymous variant in the known  
300 ASD/ID gene *ASL* (trio SA7), an alternative explanation could be the generation of an alternative  
301 splice donor by the cytosine to thymine transition at this site. However, other splice algorithms



Biallelic variants for autism....

302 such as [https://www.fruitfly.org/seq\\_tools/splice.html](https://www.fruitfly.org/seq_tools/splice.html) do not support this, and molecular  
303 experimental procedures may be needed to corroborate or refute this prediction.

#### 304 **Copy Number Variants (Table 5 & 6)**

305 Eight autosomal biallelic loss CNVs were identified among five trios using microarray data, that  
306 were subsequently validated through inspection of the WES data using IGV, and through  
307 molecular methods, using PCR and/or Sanger sequencing. Of these implicated genes,  
308 mutations/knock-outs of both *DHRS4* and *KLK15* have a neurobehavioral phenotype in mouse  
309 models (Supplementary File 1). *DNAH7* is highly expressed in brain, and both SHPK  
310 (sedoheptulokinase) and *WDR73* have high expression in cerebellum. Of the biallelic CNVs  
311 identified, *WDR73* has previously been associated with the autosomal recessive Galloway-  
312 Mowat syndrome 1 (MIM 251300), which includes microcephaly, delayed psychomotor  
313 development and cerebellar atrophy. Determining the ASD causative genetic variation in many  
314 of the probands with CNVs is difficult. The proband with the *WRD73*, *CYP2A7*, and *KLK15* CNVs  
315 (trio IABB14) also has a biallelic splice mutation in the Canavan disease gene *ASPA*. Additionally,  
316 the proband with the *SHPK* CNV (trio IABB2) also has a biallelic LoF mutation in the known ID  
317 gene *DEAF1*, and the proband with the *SIRPB1* CNV (trio IAU79) has a biallelic non-frameshift  
318 deletion in the known ID/spastic paraplegia gene *B4GALNT1*, complicating identification of the  
319 molecular causation (see Supplementary File 1). A biallelic CNV loss implicates the gene *SEMG1*  
320 in trio SMPA4, however expression of this gene is restricted to the seminal vesicle (see  
321 Supplementary File 1), and thus unlikely to be related to the ASD phenotype.

Biallelic variants for autism....

322           There are also three large, multi-genic *de novo* CNV losses among the trios, which may  
323 also be pathogenic (Supplementary Table S1).

#### 324 **Neuroanatomical Enrichment Analysis**

325           Testing for regional and cell-type specific expression did not indicate clear anatomical  
326 targets with higher expression of the candidate genes. Enrichment in the cerebellum and  
327 cerebral cortex was observed in the BrainSpan human developmental atlas, but this was not  
328 supported by either the mouse or adult human atlases. We found no consistent  
329 neuroanatomical expression pattern for the identified genes, suggesting heterogeneity of  
330 neural circuits disrupted.

#### 331 **High consanguinity coefficient correlates with identification of biallelic variants**

332           Using microarray data we calculated the consanguinity coefficient  $F_{\text{RoH}}$  using autosomal RoH for  
333 104 of the 115 trios. This included 13 trios for which LoH scores were converted to  $F_{\text{RoH}}$  using  
334 the equation  $F_{\text{RoH}} = (\text{LoH} - 0.0111) / 1.034$  (see Methods and Supplementary Materials).  
335           Comparison of the degree of consanguinity (using  $F_{\text{RoH}}$ ) between 33 trios with biallelic variants  
336 versus 20 trios with *de novo* and X-linked variants indicated a strongly significant shift (unpaired  
337 *t* test (two-tailed):  $p < 0.0001$ ;  $df=51$ ; mean  $F_{\text{RoH}}$  for biallelic variants = 0.09003, S.E.M.=0.00672,  
338  $N=33$ ; mean  $F_{\text{RoH}}$  for autosomal *de novo* and X-linked = 0.02955, S.E.M. = 0.00737,  $N=20$ ). This is  
339 also true for variants identified in known ASD/ID genes ( $p = 0.0045$ ;  $df=22$ ; mean  $F_{\text{RoH}}$  for biallelic  
340 0.08146,  $N=13$ , S.E.M.=0.01019; mean  $F_{\text{RoH}}$  for autosomal *de novo* and X-linked = 0.03282,  
341  $N=11$ , S.E.M.=0.01159).(Figure 2A). Comparison also showed clear differences in  $F_{\text{RoH}}$  levels  
342 between different cohorts, and country of ascertainment (Figure 2B & C).

Biallelic variants for autism....

343

344 **Discussion**

345 Many recent studies involving NGS in ASD have involved large cohorts, focusing predominantly  
346 on dominant/*de novo* inheritance. This focus is largely driven by the fact that autosomal  
347 recessive variants in novel genes are more difficult to identify in the outbred population.

348 Identification of candidate AR ASD genes through the study of consanguineous families should  
349 help streamline the identification of biallelic mutations through clinical genetic screening in  
350 outbred populations. Using whole exome trio analysis in consanguineous families, we have  
351 enriched for recessive variants to assess the role these variants play in ASD in populations

352 where endogamy is common. This study of 115 trios has identified WES variants for 32 trios in  
353 genes previously associated with ASD or other neurodevelopmental disorders, resulting in a  
354 diagnostic yield of 28% (18 autosomal recessive, seven autosomal *de novo* plus one maternally  
355 inherited, and six X-linked variants in known genes). With a further three trios with large, multi-

356 genic, loss CNVs validated experimentally as *de novo* and putatively pathogenic (Table 6), this  
357 yield increases to 30%. There were many other variants identified that met filtering criteria  
358 which could potentially represent novel ASD genes or targets. We present 32 new candidate  
359 autosomal recessive variants/genes, including a biallelic variant in *SHH*, a gene associated with

360 autosomal dominant holoprosencephaly. Within this cohort we identified variants in five genes  
361 that are associated with known metabolic syndromes (4.3% of the diagnosis cohort): *AGA*, *ASL*,  
362 *HTRA2*, *ASPA*, and *MTHFR*. These genes may represent better clinical management  
363 opportunities for patients, and potentially better therapies.

## Biallelic variants for autism....

364 A number of the known ID genes identified among the 115 ASD trios have also previously  
365 been reported for ASD or ASD-like features, e.g. *CC2D1A* (55,62,63), *VPS13B* (33), *DEAF1* (54),  
366 *ZNF335* (64), *ZNF292* (65,66), *MYT1L* (66,67), and *SCN2A* (59,68,69). Of the candidate genes  
367 identified here, *MSSNG*, *SFARI*, and other datasets provide putative support for the biallelic  
368 genes, with homozygous variants in *DNAH7*, *ANO10*, *DNAH8*, *CAPSL*, *CYP2A7*, and *SIRPB1*, and  
369 putative compound heterozygous variants in *DNAH7*, *DNAH8*, *SCN10A*, and *WDR90*, and for *de*  
370 *novo*/dominant genes *NCL*, *SLAMF7*, *ADGRF2*, *DGKZ*, *ATP2B1*, *CBFA2T3*, *RETN*, and *PPIL2*  
371 (Supplementary File 1).

372 For three of the known ASD or ID genes reported here, namely *ZNF292*, *SCN2A*, and *MECP2*,  
373 mutations have been identified in two unrelated trios from our cohort. Mutations in the known  
374 ASD gene *SCN2A* (68) were identified in two trios- both *de novo*. In addition, mutations were  
375 identified in three other voltage-gated sodium channel members, including a biallelic stop gain  
376 mutation in *SCN10A*, in which heterozygous gain of function missense mutations have  
377 previously been linked to familial episodic pain syndrome 2 (FEPS2; MIM 615551)(70), as well as  
378 *de novo* missense mutations in *SCN5A* and *SCN8A*. The *SCN8A* variant is predicted as damaging by  
379 all algorithms tested, and mutations in this gene have previously been linked to AD developmental and  
380 epileptic encephalopathy 13 (DEE13; MIM 614558). The *SCN5A* variant was predicted as benign by  
381 several of the algorithms and is less likely to be related to ASD in this trio. The Arg267\* mutation  
382 identified in *MECP2* in trio SMPA78 has been frequently reported in cases of Rett syndrome. However  
383 more C-terminal truncating mutations such as the Thr412Asnfs\*5 mutation in trio IAU54 typically have a  
384 significantly milder phenotype(71).

## Biallelic variants for autism....

385 For some of the autosomal recessive candidate genes, there is additional support from  
386 animal models. For instance, *Rasal2* (MGI:2443881) and *Vps16* (MGI:2136772) knockout mice  
387 have behavioral/neurological and nervous system phenotypes  
388 (<http://www.informatics.jax.org/>; Supplementary File 1). Additional discussion of mouse  
389 models relevant to the candidate genes is provided in Supplementary Materials.

390 There are several trios for which there are two or more candidate variants (Supplementary  
391 File 1). For some of these, there may be a variant that clearly delivers a more plausible  
392 etiopathological explanation. For instance, for trio SMPA3 the biallelic change in *MTHFR*; for  
393 trio IAH2, the biallelic LoF change in *TECPR2* (SPG49; MIM 615031; ID (30); hereditary sensory  
394 neuropathy with ID (72)); for trio IABB2, the biallelic LoF variant in (*NEDHELS*; MIM 617171); for  
395 trio IABB14, the biallelic splice mutation in *ASPA* (Canavan disease; MIM 271900).

396 Since our initial methodology used relatively stringent MAF cut-off criteria for biallelic  
397 variants ( $<0.001$ ), we attempted to justify this level by reiterating the analysis but with lower  
398 thresholds ( $<0.01$ ). Using the more relaxed criteria resulted in just two additional candidate  
399 variants, in the genes *CLCA4* (gnomAD South Asian MAF=1.72E-3), and *RASAL2* (gnomAD South  
400 Asian MAF=6E-3), but none in known neurodevelopmental genes. Our methodology was  
401 particularly stringent regarding *de novo* nonsynonymous variants, owing to the large number of  
402 likely spurious calls, and the inclusion of only variants predicted as damaging by all algorithms  
403 used may have excluded some *bona fide* mutations. Other variants, particularly intronic or  
404 intergenic, would also likely be missed by our approach. Also, a proportion of exons, and  
405 particularly in GC-rich regions, are either missed or have low coverage in WES. Follow-up with

## Biallelic variants for autism....

406 whole genome sequencing could be considered as a possible next step. However, parsing and  
407 assessing rare non-coding variants is particularly challenging.

408 It was recently estimated in the DDD cohort that recessive variants make up 3.6% of  
409 diagnoses, whereas *de novo* variants contribute 48.6% of variants (38). The same study also  
410 compared homozygous variants in a narrowly defined group of Pakistani Ancestry in the British  
411 Isles (PABI), which is most like our cohort (38). The PABI cohort had 356 (333 undiagnosed)  
412 probands, 110 of whom (30.9%) had biallelic coding candidate variants, approximately half of  
413 which are in known DD genes and half in novel candidates (38). For comparison, our study  
414 reports very similar yields for recessive variants, with 15% of probands with biallelic variants in  
415 known ASD/ID genes (17/115), or 30% including those with biallelic variants in novel candidate  
416 genes (35/115). We report 28 *de novo* variants (20 autosomal, five X-linked, three CNVs) in 17  
417 of 115 individuals (15%), which is somewhat lower than those reported for the PABI cohort  
418 (29.8%). This difference is most likely due to differences in the methodologies or stringency  
419 used for calling *de novo* variants in the respective studies.

420 Comparison of consanguinity ( $F_{RoH}$ ) between trios with biallelic variants (either known or  
421 candidates) versus trios with *de novo* and X-linked variants indicated a strongly significant shift..  
422 Thus, unsurprisingly, the chances of finding biallelic rare variants is strongly associated with  
423 higher consanguinity, and should be a consideration for diagnostic genetic analysis.

424 Overall, the findings demonstrate the importance of autosomal recessive mutations in  
425 ASD in countries, or in cohorts, with high rates of consanguinity. In countries where  
426 consanguinity is rare, when screening ASD individuals' genomes attention should still be paid to

Biallelic variants for autism....

427 the relatedness of the parents, and, for those with a high F-coefficient, attention should be  
428 focused on biallelic variants. Additionally, the candidate genes reported here should be  
429 examined for both autozygous *and* allozygous mutations in outbred populations, just as would  
430 be done for more established autosomal recessive gene disorders.

431

#### 432 **Declaration of Interests Statement**

433 L.F. owns shares in Quince Therapeutics and has received consulting fees from PeopleBio Co., GC  
434 Therapeutics Inc., Cortexyme Inc., and Keystone Bio. M.A. is co-founder and director of Institute of  
435 Omics and Health Research, Lahore, a research organization. The organization was not involved  
436 in the research on which this manuscript is based. All other authors declare no competing  
437 interests.

438

#### 439 **Acknowledgements**

440 The authors thank the families for their participation in this study. We acknowledge the  
441 assistance of Natalie Freeman with PLINK microarray analysis, and of Stephen Pastore with the  
442 preparation of violin plots using R software. This work was supported by grants from the  
443 Canadian Institutes of Health Research to JBV (#MOP-102758 and #PJT-156402), also a Brain &  
444 Behavior Research Foundation (BBRF/NARSAD) Young Investigator Award to NV. RH was  
445 supported by a Peterborough K.M. Hunter Charitable Foundation Graduate Scholarship. AR and  
446 AH were supported by International Research Fellowship Program scholarships from the  
447 Pakistani Higher Education Commission. CS was supported by a Summer University Research

Biallelic variants for autism....

448 Program award from the Institute of Medical Science, University of Toronto. Computations  
449 were performed on the CAMH Specialized Computing Cluster. The SCC is funded by The Canada  
450 Foundation for Innovation, Research Hospital Fund. Additional acknowledgements are included  
451 in Supplementary Materials

#### 452 **Data and code availability**

453 New variants reported here are available through ClinVar SUB14665852, and SCV accession  
454 numbers are included in Supplementary File 1. Microarray genotype data and whole exome sequence  
455 data will be made available from the corresponding author upon request.

456

#### 457 **References**

- 458 1. Helt M, Kelley E, Kinsbourne M, Pandey J, Boorstein H, Herbert M, Fein D (2008): Can children  
459 with autism recover? If so, how? *Neuropsychol Rev* 18: 339–366.
- 460 2. Mason D, Capp SJ, Stewart GR, Kempton MJ, Glaser K, Howlin P, Happé F (2021): A Meta-  
461 analysis of Outcome Studies of Autistic Adults: Quantifying Effect Size, Quality, and  
462 Meta-regression. *J Autism Dev Disord* 51: 3165–3179.
- 463 3. Lai M-C, Kasseh C, Besney R, Bonato S, Hull L, Mandy W, *et al.* (2019): Prevalence of co-  
464 occurring mental health diagnoses in the autism population: a systematic review and  
465 meta-analysis. *Lancet Psychiatry* 6: 819–829.
- 466 4. Baxter AJ, Brugha TS, Erskine HE, Scheurer RW, Vos T, Scott JG (2015): The epidemiology and  
467 global burden of autism spectrum disorders. *Psychol Med* 45: 601–613.



Biallelic variants for autism....

- 468 5. Elsabbagh M, Divan G, Koh Y-J, Kim YS, Kauchali S, Marcín C, *et al.* (2012): Global Prevalence  
469 of Autism and Other Pervasive Developmental Disorders. *Autism Res* 5: 160–179.
- 470 6. Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, Charman T (2006):  
471 Prevalence of disorders of the autism spectrum in a population cohort of children in  
472 South Thames: the Special Needs and Autism Project (SNAP). *Lancet Lond Engl* 368:  
473 210–215.
- 474 7. Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal  
475 Investigators, Centers for Disease Control and Prevention (CDC) (2014): Prevalence of  
476 autism spectrum disorder among children aged 8 years - autism and developmental  
477 disabilities monitoring network, 11 sites, United States, 2010. *Morb Mortal Wkly Rep*  
478 *Surveill Summ Wash DC* 2002 63: 1–21.
- 479 8. Kim YS, Leventhal BL, Koh Y-J, Fombonne E, Laska E, Lim E-C, *et al.* (2011): Prevalence of  
480 autism spectrum disorders in a total population sample. *Am J Psychiatry* 168: 904–912.
- 481 9. Lundström S, Reichenberg A, Anckarsäter H, Lichtenstein P, Gillberg C (2015): Autism  
482 phenotype versus registered diagnosis in Swedish children: prevalence trends over 10  
483 years in general population samples. *BMJ* 350: h1961.
- 484 10. Maenner MJ (2020): Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years  
485 — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States,  
486 2016. *MMWR Surveill Summ* 69. <https://doi.org/10.15585/mmwr.ss6904a1>
- 487 11. Maenner MJ (2023): Prevalence and Characteristics of Autism Spectrum Disorder Among  
488 Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11

Biallelic variants for autism....

- 489 Sites, United States, 2020. *MMWR Surveill Summ* 72.
- 490 <https://doi.org/10.15585/mmwr.ss7202a1>
- 491 12. Fombonne E (2018): Editorial: The rising prevalence of autism. *J Child Psychol Psychiatry* 59:
- 492 717–720.
- 493 13. Hansen SN, Schendel DE, Parner ET (2015): Explaining the increase in the prevalence of
- 494 autism spectrum disorders: the proportion attributable to changes in reporting
- 495 practices. *JAMA Pediatr* 169: 56–62.
- 496 14. Lord C, Brugha T, Charman T, Cusack J, Dumas G, Frazier T, *et al.* (2020): Autism spectrum
- 497 disorder. *Nat Rev Dis Primer* 6: 5.
- 498 15. Rødgaard E-M, Jensen K, Vergnes J-N, Soulières I, Mottron L (2019): Temporal Changes in
- 499 Effect Sizes of Studies Comparing Individuals With and Without Autism: A Meta-analysis.
- 500 *JAMA Psychiatry* 76: 1124–1132.
- 501 16. Hossain MD, Ahmed HU, Jalal Uddin MM, Chowdhury WA, Iqbal MS, Kabir RI, *et al.* (2017):
- 502 Autism Spectrum disorders (ASD) in South Asia: a systematic review. *BMC Psychiatry* 17:
- 503 281.
- 504 17. Imran N, Bhatti MR, Anwar A, Najmi F, Haider II (2012): Children’s Mental Health: Pattern of
- 505 referral, distribution of disorders and service use in child psychiatry outpatient setting.
- 506 *Pak J Med Sci* 28: 22–26.
- 507 18. Syed EU, Hussein SA, Yousafzai AW (2007): Developing Services with Limited Resources:
- 508 Establishing a CAMHS in Pakistan. *Child Adolesc Ment Health* 12: 121–124.

Biallelic variants for autism....

- 509 19. Tareen A, Mirza I, Minhas A, Minhas F, Rahman A (2009): Developing a child and adolescent  
510 mental health service in a low-income country: a global partnership model. *Psychiatr*  
511 *Bull* 33: 181–183.
- 512 26. Sarwat A, Ali SMI, Ejaz MS. Mental health comorbidity in children: a hospital based study  
513 in child psychiatry clinic. *Pak J Med Sci*. 2009;25(6):982–5.
- 514 21. Minhas A, Vajaratkar V, Divan G, Hamdani SU, Leadbitter K, Taylor C, *et al.* (2015): Parents’  
515 perspectives on care of children with autistic spectrum disorder in South Asia – Views  
516 from Pakistan and India. *Int Rev Psychiatry* 27: 247–256.
- 517 22. Rauf NK, Anis-ul-Haq null, Aslam N, Anjum U (2014): Characteristic symptoms and adaptive  
518 behaviors of children with autism. *J Coll Physicians Surg--Pak JCPSP* 24: 658–662.
- 519 23. Bunday S, Alam H (1993): A five-year prospective study of the health of children in different  
520 ethnic groups, with particular reference to the effect of inbreeding. *Eur J Hum Genet*  
521 *EJHG* 1: 206–219.
- 522 24. Modell B, Darr A (2002): Science and society: genetic counselling and customary  
523 consanguineous marriage. *Nat Rev Genet* 3: 225–229.
- 524 25. Harripaul R, Vasli N, Mikhailov A, Rafiq MA, Mittal K, Windpassinger C, *et al.* (2018):  
525 Mapping autosomal recessive intellectual disability: combined microarray and exome  
526 sequencing identifies 26 novel candidate genes in 192 consanguineous families. *Mol*  
527 *Psychiatry* 23: 973–984.
- 528 26. Riazuddin S, Hussain M, Razzaq A, Iqbal Z, Shahzad M, Polla DL, *et al.* (2017): Exome  
529 sequencing of Pakistani consanguineous families identifies 30 novel candidate genes for  
530 recessive intellectual disability. *Mol Psychiatry* 22: 1604–1614.

Biallelic variants for autism....

- 531 27. Hu H, Kahrizi K, Musante L, Fattahi Z, Herwig R, Hosseini M, *et al.* (2018): Genetics of  
532 intellectual disability in consanguineous families. *Mol Psychiatry*.  
533 <https://doi.org/10.1038/s41380-017-0012-2>
- 534 28. Najmabadi H, Hu H, Garshasbi M, Zemojtel T, Abedini SS, Chen W, *et al.* (2011): Deep  
535 sequencing reveals 50 novel genes for recessive cognitive disorders. *Nature* 478: 57–63.
- 536 29. Reuter MS, Tawamie H, Buchert R, Hosny Gebril O, Froukh T, Thiel C, *et al.* (2017):  
537 Diagnostic Yield and Novel Candidate Genes by Exome Sequencing in 152  
538 Consanguineous Families With Neurodevelopmental Disorders. *JAMA Psychiatry* 74:  
539 293–299.
- 540 30. Anazi S, Maddirevula S, Salpietro V, Asi YT, Alsahli S, Alhashem A, *et al.* (2017): Expanding  
541 the genetic heterogeneity of intellectual disability. *Hum Genet* 136: 1419–1429.
- 542 31. Morrow EM, Yoo S-Y, Flavell SW, Kim T-K, Lin Y, Hill RS, *et al.* (2008): Identifying autism loci  
543 and genes by tracing recent shared ancestry. *Science* 321: 218–223.
- 544 32. Al-Mubarak B, Abouelhoda M, Omar A, AlDhalaan H, Aldosari M, Nester M, *et al.* (2017):  
545 Whole exome sequencing reveals inherited and de novo variants in autism spectrum  
546 disorder: a trio study from Saudi families. *Sci Rep* 7: 5679.
- 547 33. Yu TW, Chahrour MH, Coulter ME, Jiralerspong S, Okamura-Ikeda K, Ataman B, *et al.* (2013):  
548 Using whole-exome sequencing to identify inherited causes of autism. *Neuron* 77: 259–  
549 273.
- 550 34. Mamidala MP, Kalikiri MK, Praveen Kumar PTV, Rajesh N, Vallamkonda OR, Rajesh V (2015):  
551 Consanguinity in India and its association with autism spectrum disorder. *Autism Res Off*  
552 *J Int Soc Autism Res* 8: 224–228.

Biallelic variants for autism....

- 553 35. Lim ET, Raychaudhuri S, Sanders SJ, Stevens C, Sabo A, MacArthur DG, *et al.* (2013): Rare  
554 complete knockouts in humans: population distribution and significant role in autism  
555 spectrum disorders. *Neuron* 77: 235–242.
- 556 36. Howrigan DP, Simonson MA, Davies G, Harris SE, Tenesa A, Starr JM, *et al.* (2016): Genome-  
557 wide autozygosity is associated with lower general cognitive ability. *Mol Psychiatry* 21:  
558 837–843.
- 559 37. Kaiser VB, Svinti V, Prendergast JG, Chau Y-Y, Campbell A, Patarcic I, *et al.* (2015):  
560 Homozygous loss-of-function variants in European cosmopolitan and isolate  
561 populations. *Hum Mol Genet* 24: 5464–5474.
- 562 38. Martin HC, Jones WD, McIntyre R, Sanchez-Andrade G, Sanderson M, Stephenson JD, *et al.*  
563 (2018): Quantifying the contribution of recessive coding variation to developmental  
564 disorders. *Science* 362: 1161–1164.
- 565 39. Kahrizi K, Hu H, Hosseini M, Kalscheuer VM, Fattahi Z, Beheshtian M, *et al.* (2019): Effect of  
566 inbreeding on intellectual disability revisited by trio sequencing. *Clin Genet* 95: 151–159.
- 567 40. Ramaswami G, Geschwind DH (2018): Genetics of autism spectrum disorder. *Handb Clin*  
568 *Neurol* 147: 321–329.
- 569 41. McQuillan R, Leutenegger A-L, Abdel-Rahman R, Franklin CS, Pericic M, Barac-Lauc L, *et al.*  
570 (2008): Runs of homozygosity in European populations. *Am J Hum Genet* 83: 359–372.
- 571 42. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP  
572 (2011): Integrative genomics viewer. *Nat Biotechnol* 29: 24–26.

Biallelic variants for autism....

- 573 43. Yuen RKC, Merico D, Cao H, Pellecchia G, Alipanahi B, Thiruvahindrapuram B, *et al.* (2016):  
574 Genome-wide characteristics of de novo mutations in autism. *NPJ Genomic Med* 1:  
575 160271–1602710.
- 576 44. De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, *et al.* (2014): Synaptic,  
577 transcriptional and chromatin genes disrupted in autism. *Nature* 515: 209–215.
- 578 45. Yang C, Li J, Wu Q, Yang X, Huang AY, Zhang J, *et al.* (2018): AutismKB 2.0: a knowledgebase  
579 for the genetic evidence of autism spectrum disorder. *Database J Biol Databases*  
580 *Curation* 2018. <https://doi.org/10.1093/database/bay106>
- 581 46. Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, Shen EH, Ng L, Miller JA, *et al.* (2012): An  
582 anatomically comprehensive atlas of the adult human brain transcriptome. *Nature* 489:  
583 391–399.
- 584 47. Li M, Santpere G, Imamura Kawasawa Y, Evgrafov OV, Gulden FO, Pochareddy S, *et al.*  
585 (2018): Integrative functional genomic analysis of human brain development and  
586 neuropsychiatric risks. *Science* 362. <https://doi.org/10.1126/science.aat7615>
- 587 48. Zeisel A, Hochgerner H, Lönnerberg P, Johnsson A, Memic F, van der Zwan J, *et al.* (2018):  
588 Molecular Architecture of the Mouse Nervous System. *Cell* 174: 999-1014.e22.
- 589 49. Benjamini Y, Hochberg Y (1995): Controlling the False Discovery Rate: A Practical and  
590 Powerful Approach to Multiple Testing. *J R Stat Soc Ser B Methodol* 57: 289–300.
- 591 50. Bomkamp C, Tripathy SJ, Bengtsson Gonzales C, Hjerling-Leffler J, Craig AM, Pavlidis P  
592 (2019): Transcriptomic correlates of electrophysiological and morphological diversity  
593 within and across excitatory and inhibitory neuron classes. *PLoS Comput Biol* 15:  
594 e1007113.

Biallelic variants for autism....

- 595 51. Basel-Vanagaite L, Attia R, Yahav M, Ferland RJ, Anteki L, Walsh CA, *et al.* (2006): The  
596 CC2D1A, a member of a new gene family with C2 domains, is involved in autosomal  
597 recessive non-syndromic mental retardation. *J Med Genet* 43: 203–210.
- 598 52. Perez Y, Menascu S, Cohen I, Kadir R, Basha O, Shorer Z, *et al.* (2018): RSRC1 mutation  
599 affects intellect and behaviour through aberrant splicing and transcription,  
600 downregulating IGFBP3. *Brain J Neurol* 141: 961–970.
- 601 53. Maddirevula S, AlZahrani F, Anazi S, Almureikhi M, Ben-Omran T, Abdel-Salam GMH, *et al.*  
602 (2018): GWAS signals revisited using human knockouts. *Genet Med Off J Am Coll Med*  
603 *Genet* 20: 64–68.
- 604 54. Nabais Sá MJ, Jensik PJ, McGee SR, Parker MJ, Lahiri N, McNeil EP, *et al.* (2019): De novo  
605 and biallelic DEAF1 variants cause a phenotypic spectrum. *Genet Med Off J Am Coll Med*  
606 *Genet* 21: 2059–2069.
- 607 55. Manzini MC, Xiong L, Shaheen R, Tambunan DE, Di Costanzo S, Mitisalis V, *et al.* (2014):  
608 CC2D1A regulates human intellectual and social function as well as NF-κB signaling  
609 homeostasis. *Cell Rep* 8: 647–655.
- 610 56. Douzgou S, Petersen MB (2011): Clinical variability of genetic isolates of Cohen syndrome.  
611 *Clin Genet* 79: 501–506.
- 612 57. Rajab A, Schuelke M, Gill E, Zwirner A, Seifert F, Morales Gonzalez S, Knierim E (2015):  
613 Recessive DEAF1 mutation associates with autism, intellectual disability, basal ganglia  
614 dysfunction and epilepsy. *J Med Genet* 52: 607–611.

Biallelic variants for autism....

- 615 58. Smith DR, Stanley CM, Foss T, Boles RG, McKernan K (2017): Rare genetic variants in the  
616 endocannabinoid system genes CNR1 and DAGLA are associated with neurological  
617 phenotypes in humans. *PLoS One* 12: e0187926.
- 618 59. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, *et al.* (2012): De  
619 novo mutations revealed by whole-exome sequencing are strongly associated with  
620 autism. *Nature* 485: 237–241.
- 621 60. Pillai NR, Yubero D, Shayota BJ, Oyarzábal A, Ghosh R, Sun Q, *et al.* (2019): Loss of CLTRN  
622 function produces a neuropsychiatric disorder and a biochemical phenotype that mimics  
623 Hartnup disease. *Am J Med Genet A* 179: 2459–2468.
- 624 61. Berciano J, García A, Gallardo E, Peeters K, Pelayo-Negro AL, Álvarez-Paradelo S, *et al.*  
625 (2017): Intermediate Charcot-Marie-Tooth disease: an electrophysiological reappraisal  
626 and systematic review. *J Neurol* 264: 1655–1677.
- 627 62. Mirzaa GM, Chong JX, Piton A, Popp B, Foss K, Guo H, *et al.* (2020): De novo and inherited  
628 variants in ZNF292 underlie a neurodevelopmental disorder with features of autism  
629 spectrum disorder. *Genet Med* 22: 538–546.
- 630 63. Sener EF, Onal MG, Dal F, Nalbantoglu U, Ozkul Y, Canatan H, Oztop DB (2020): Novel  
631 alterations of CC2D1A as a candidate gene in a Turkish sample of patients with autism  
632 spectrum disorder. *Int J Neurosci* 1–8.
- 633 64. Wu J, Yu P, Jin X, Xu X, Li J, Li Z, *et al.* (2018): Genomic landscapes of Chinese sporadic  
634 autism spectrum disorders revealed by whole-genome sequencing. *J Genet Genomics Yi*  
635 *Chuan Xue Bao* 45: 527–538.



Biallelic variants for autism....

- 636 65. Guo H, Wang T, Wu H, Long M, Coe BP, Li H, *et al.* (2018): Inherited and multiple de novo  
637 mutations in autism/developmental delay risk genes suggest a multifactorial model. *Mol*  
638 *Autism* 9: 64.
- 639 66. Wang T, Guo H, Xiong B, Stessman HAF, Wu H, Coe BP, *et al.* (2016): De novo genic  
640 mutations among a Chinese autism spectrum disorder cohort. *Nat Commun* 7: 13316.
- 641 67. Coursimault J, Guerrot A-M, Morrow MM, Schramm C, Zamora FM, Shanmugham A, *et al.*  
642 (2021): MYT1L-associated neurodevelopmental disorder: description of 40 new cases  
643 and literature review of clinical and molecular aspects. *Hum Genet.*  
644 <https://doi.org/10.1007/s00439-021-02383-z>
- 645 68. Weiss LA, Escayg A, Kearney JA, Trudeau M, MacDonald BT, Mori M, *et al.* (2003): Sodium  
646 channels SCN1A, SCN2A and SCN3A in familial autism. *Mol Psychiatry* 8: 186–194.
- 647 69. Jiang Y, Yuen RKC, Jin X, Wang M, Chen N, Wu X, *et al.* (2013): Detection of clinically  
648 relevant genetic variants in autism spectrum disorder by whole-genome sequencing. *Am*  
649 *J Hum Genet* 93: 249–263.
- 650 70. Faber CG, Lauria G, Merkies ISJ, Cheng X, Han C, Ahn H-S, *et al.* (2012): Gain-of-function  
651 Nav1.8 mutations in painful neuropathy. *Proc Natl Acad Sci U S A* 109: 19444–19449.
- 652 71. Bebbington A, Percy A, Christodoulou J, Ravine D, Ho G, Jacoby P, *et al.* (2010): Updating the  
653 profile of C-terminal MECP2 deletions in Rett syndrome. *J Med Genet* 47: 242–248.
- 654 72. Neuser S, Brechmann B, Heimer G, Brösse I, Schubert S, O’Grady L, *et al.* (2021): Clinical,  
655 neuroimaging, and molecular spectrum of TECPR2-associated hereditary sensory and  
656 autonomic neuropathy with intellectual disability. *Hum Mutat* 42: 762–776.

Biallelic variants for autism....

- 657 73. Schopler E, Reichler RJ, DeVellis RF, Daly K (1980): Toward objective classification of  
658 childhood autism: Childhood Autism Rating Scale (CARS). *J Autism Dev Disord* 10: 91–  
659 103.
- 660 74. Lord C, Rutter M, Le Couteur A (1994): Autism Diagnostic Interview-Revised: a revised  
661 version of a diagnostic interview for caregivers of individuals with possible pervasive  
662 developmental disorders. *J Autism Dev Disord* 24: 659–685.
- 663 75. Lord C, Rutter M, Goode S, Heemsbergen J, Jordan H, Mawhood L, Schopler E (1989):  
664 Autism diagnostic observation schedule: a standardized observation of communicative  
665 and social behavior. *J Autism Dev Disord* 19: 185–212.
- 666 76. American Psychiatric Association (2000): *Diagnostic and Statistical Manual of Mental*  
667 *Disorders, 4th Edition, Text Revision*, 4th edition. Washington, DC: American Psychiatric  
668 Association.
- 669 77. Ehlers S, Gillberg C, Wing L (1999): A screening questionnaire for Asperger syndrome and  
670 other high-functioning autism spectrum disorders in school age children. *J Autism Dev*  
671 *Disord* 29: 129–141.
- 672 78. Skuse D, Warrington R, Bishop D, Chowdhury U, Lau J, Mandy W, Place M (2004): The  
673 developmental, dimensional and diagnostic interview (3di): a novel computerized  
674 assessment for autism spectrum disorders. *J Am Acad Child Adolesc Psychiatry* 43: 548–  
675 558.
- 676 79. American Psychiatric Association, American Psychiatric Association, DSM-5 Task Force  
677 (2013): *Diagnostic and Statistical Manual of Mental Disorders: DSM-5*. Retrieved  
678 December 14, 2016, from <http://dsm.psychiatryonline.org/book.aspx?bookid=556>

Biallelic variants for autism....

- 679 80. World Health Organization (2010): The ICD-10 Classification of Mental and Behavioural  
680 Disorders. World Health Organization. Retrieved from  
681 <https://www.who.int/classifications/icd/en/bluebook.pdf>
- 682 81. Packer JS, Maxwell EK, O'Dushlaine C, Lopez AE, Dewey FE, Chernomorsky R, *et al.* (2016):  
683 CLAMMS: a scalable algorithm for calling common and rare copy number variants from  
684 exome sequencing data. *Bioinformatics* 32: 133–135.
- 685
- 686

687 **Table 1:** Cohort Description and clinical assessment.

<b>Cohort ID (Recruited By)</b>	<b>Institute</b>	<b>Nationality (Age range)</b>	<b>Number of Trios (Number of DNAs)</b>	<b>Proband Male: Female</b>	<b>Instruments and diagnostic system</b>	<b>Assessors</b>
SMPA (Ansa Rabia, Saqib Mahmood, Shazia Maqbool)	University of Health Sciences and Children Hospital, Lahore	Pakistan	54 (162)	42:12	Childhood Autism Rating Scale (CARS)(73) DSM IV	Physicians with expertise in neurodevelopmental disorders
IAU (Dr. Sasanfar)	Children’s Health and Evaluation Project/ Special Education Organization	Iran (4-11)	27 (81)	23:4	ADI-R (74) and ADOS (75) (DSM-IV-TR) (76); SCQ (50)	Certified Physicians
IABB (Dr. Bita Bozorgmehr)	Shahid Beheshti Medical University, Teheran	Iran	10 (30)	9:2	Autism Spectrum Screening Questionnaire (77) DSM IV	Dr Bita Bozorgmehr
SA (Laila Al Ayadhi)	Autism Treatment Centre, King Saud University, Riyadh	Saudi Arabia (2-12)	13 (39)	12:1	ADI-R (74), Autism Diagnostic Observation Schedule (ADOS) (75) and 3DI (Developmental, dimensional diagnostic interview) scales (78) Childhood Autism Rating Scale (CARS)(73); DSM IV	Dr Laila Al Ayadhi
Autism (Raheel Qamar, Maleeha Azam and Zehra Agha)	COMSATS University, Islamabad, and National Rural Support Program	Pakistan	4 (12)	4:4	Childhood Autism Rating Scale (CARS)(73)	Dr Maimoona Siddiqui

Biallelic variants for autism....

RQPA (Raheel Qamar, Maleeha Azam and Zehra Agha)	and the Ghazi Barotha Taraqiata iDara		4 (12)		DSM-5 (79) and ICD-10 criteria (80)	Dr Maimoona Siddiqui
IAH (Abolfazl Heidari)	Qazvin Medical University, Qazvin	Iran	3 (9)	2:1	DSM IV	Dr Hossein Mojdehipanah
Total			115 (345)	91:24		

688

689

Biallelic variants for autism....

690 **Table 2: Biallelic/homozygous variants:** Genes previously reported as pathogenic for ASD/ID or other disorder are indicated, with  
 691 annotation using (in order of priority): OMIM: <https://omim.org/>; SFARI ASD genes <https://gene.sfari.org/>; DDD gene2phenotype  
 692 genes: <https://www.ebi.ac.uk/gene2phenotype/>; Geisinger developmental brain disorder gene database:  
 693 <https://dbd.geisingeradmi.org/>; NPdenovo: <http://www.wzgenomics.cn/NPdenovo/>; Gene4denovo:  
 694 <http://www.genemed.tech/gene4denovo/search>. Genes previously unreported for ASD or ID are in bold type. Control population  
 695 frequencies show are from gnomAD (all, and for South Asian sub-population). All variants were validated by IGV (Integrated  
 696 Genomics Viewer; Broad Institute) and by Sanger sequencing. Validations are shown in Supplementary Materials. Allele frequencies  
 697 are from gnomAD v2.1.1 (www. <https://gnomad.broadinstitute.org/>; accessed June 2022).

Variant	Family	Chr	Coordinates (hg19)	Ref.	Alt.	Gene	Variant Type	cDNA/Amino Acid Change	gnomAD All Freq.	gnomAD S. Asian Freq.
1	SMPA3	1	11855404	C	A	MTHFR (29)(MIM 236250; SFARI score 2)	nonsynonymous	NM_001330358.2: exon6: c. 905G>T: p. Gly302Val	3.99E-06	3.27E-05
2	ABB16	1	87029377	G	A	<b>CLCA4</b>	nonsynonymous	NM_012128.3:c.482G>A:p.Arg161Gln	4.11E-04	1.72E-03
3	SMPA4	1	152193673-152193682	GACGTTT C TG	-	<b>HRNR</b>	frameshift del	NM_001009931.3: exon3: c.423_432del:p.Arg142Glufs*15	4.37E-05	3.59E-4
4	SMPA76	1	166891855-166891856	CT	-	<b>ILDR2</b>	frameshift del	NM_199351.3: exon8: c.1187_1188del: p. Glu396Glyfs*39	3.98E-06	3.27E-05
5	SMPA3	1	178425880	C	A	<b>RASAL2</b>	Nonsynonymous	NM_004841.3: exon11: c.1813C>A: p. Leu605Ile	6.72E-4	6.04E-3
6	SMPA40	1	197621364	C	A	<b>DENND1B</b>	Splicing	NM_001195215.1: exon7: c.447+1G>T	0	0
7	Autism8	2	74759786	G	T	HTRA2 (MIM 617248)	Nonsynonymous	NM_013247.3: exon7: c.1156G>T: p. Asp386Tyr	7.95E-06	6.53E-05
8	SMPA19	3	38802185	C	A	<b>SCN10A</b>	Stopgain	NM_001293306.2: exon7: c.937G>T; p. Gly313*	3.98E-06	3.27E-05
9	SMPA76	3	43593070	C	A	<b>ANO10</b> (spinocerebellar ataxia 10, MIM 613728)	Nonsynonymous	NM_001346463.2:exon11:c.1679G>T;p.Cys560Phe	0	0

Biallelic variants for autism....

10	SA15	3	47164429	G	C	SETD2 (LLS (AD) MIM 616831; SFARI score 1; Geisinger Tier 1)	Nonsynonymous	NM_001349370.3: exon2:c.1565C>G: p. Ser522Cys	0	0
11	SMPA27	3	134911657	T	C	EPHB1 (SFARI score 3)	Nonsynonymous	NM_004441.3: exon11: c.2122T>C: p. Phe708Lys	4.01E-06	3.27E-05
12	Autism3	3	157840002	C	T	RSRC1 (MRT70; MIM 618402; SFARI score S)	Stopgain	NM_001271834.2: exon2:c.109C>T: p. Arg37*	0	0
13	SMPA8	3	169524635	C	T	LRRC34	Splicing	NM_001172779.1: exon5: c.528+1G>A	4.08E-06	03.44E-05
14	SMPA40	4	111480831	C	T	ENPEP	Stop gain	NM_001977.4: exon19: c.2671C>T; p.Arg891*	1.791E-4	1.34E-03
15	RQPA12	4	178360822	G	A	AGA (MIM 208400)	Nonsynonymous	NM_000027.3: exon3: c.302C>T: p. Ala101Val	3.98E-06	3.27E-05
16	SMPA35	4	185033930	CAT	C	ENPP6	frameshift del	NM_153343.3: exon6: c.886_887del: p.Met296Aspfs*28	0	0
17	IABB11	5	35910583	C	T	CAPSL	Nonsynonymous	NM_144647.3:c.200G>A:p.Gly67Glu	0	0
18	Autism8	5	150846823	-	CTGG	SLC36A1	frameshift ins	NM_001308150.2: exon6:c.487_490dup: p. Asp164Glyfs*28	8.01E-06	6.6E-05
19	IAU56	5	154199963	C	-	FAXDC2	frameshift del	NM_032385.3: exon9: c.915delG: p.Thr306Profs*100	5.28E-05	3.93E-04
20	SMPA48	6	13634723	C	G	RANBP9	Nonsynonymous	NM_005493.3: exon11: c.1735G>C: p. Gly579Arg	2.89E-05	1.06E-04
21	IABB8	6	38851674	A	T	DNAH8	Nonsynonymous	NM_001206927.2: exon56: c.8159A>T: p. Asp2720Val	1.24E-05	1.02E-04
22	IAU7	7	47944924	T	C	PKD1L1 (AR laterality defects; MIM 616205)	Splicing	NM_138295.3: exon11: c.1523-2A>G	0	0
23	SA7	7	65551627	C	T	ASL (MIM 207900)#	Nonsynonymous	NM_001024943.2: exon6:c.502C>T: p. Arg168Cys	7.98E-06	0
24	IABB7	7	99720009	G	C	CNPY4	Splicing	NM_152755.1: exon2: c.245+1G>C	2.12E-05	0
25	IAU79	7	150174821	TCC	T	GIMAP8	frameshift del	NM_175571.3: exon5: c.1952_1953del: p. Gln652Serfs*6	0	0
26	SMPA11	7	155604611	T	A	SHH (HPE3 (AD) MIM 142945)	Nonsynonymous	NM_000193.4: exon1: c.206A>T: p. Asn69Ile	2.39E-06	1.96E-4
27	IABB3	8	100155379	AG	A	VPS13B (COH1 MIM 216550; SFARI score 1; Geisinger AR)	frameshift del	NM_015243.3: exon13: c.1829delG: p. Ser610Thrfs*3	0	0

Biallelic variants for autism....

28	SA4	9	5805613	T	C	<b>ERMP1</b>	Nonsynonymous	NM_024896.3: exon9: c.1721A>G: p.His574Arg	0	0
29	IABB2	11	679701	G	GA	DEAF1 (MIM 617171; SFARI score 1; Geisinger AR)	frameshift ins	NM_001293634.1: exon6: c.845dupT: p. Ala283Argfs*20	0	0
30	SMPA11	11	6477889	C	A	<b>TRIM3</b>	Nonsynonymous	NM_033278.3:exon6:c.1067G>T:p.Arg356Leu	0	0
31	SMPA20	11	47305749	A	G	MADD (27,30)	Nonsynonymous	NM_001135943.2: exon11: c. 1883A>G: p. Tyr628Cys	1.99E-05	1.63E-04
32	SMPA21	11	61495635	C	G	<b>DAGLA</b> (SFARI score 2)	Stopgain	NM_006133.3: exon7:c.647C>G: p. Ser216*	0	0
33	SMPA80	11	67290028	C	T	<b>CABP2</b> (Deafness, MIM 607314)	Nonsynonymous	NM_016366.3: exon2: c.202G>A: p. Ala68Thr	5.70E-05	3.48E-04
34	SMPA8	11	118403863	A	G	<b>TMEM25</b>	Nonsynonymous	NM_001144036.2: exon3: c. 302A>G: p. Asn101Ser	3.64E-05	2.62E-04
35	IAU79	12	58021514_58021534	GGGAAG CCGACG AGCTCGT GGT	G	B4GALNT1 (Spastic paraplegia 26; MIM 609195 ID reported in some cases)	nonframeshift del	NM_001276468.2: exon9: c.1094_1114del: p.His365_Phe372del	0	0
36	IABB10	12	69263140	C	G	<b>CPM</b>	Nonsynonymous	NM_001005502.2: exon6: c.752G>C: p. Gly251Ala	0	0
37	IABB11	12	118199039	G	A	<b>KSR2</b>	Nonsynonymous	NM_173598.6:exon4:c.763C>T;p.Arg255Trp	2.196E-05	0
38	SMPA8	14	65032074	G	C	<b>PPP1R36</b>	Splicing	NM_172365: exon5: c.270-1G>C	1.21E-05	9.99E-05
39	IAH2	14	102963429	TGTGGG GACCGC CTG	T	TECPR2 Anazi et al, 2017 PMID 27431290); Neuropathy, hereditary sensory and autonomic, type IX, with developmental delay (HSAN9): MIM 615031	frameshift del	NM_014844.3: exon18: c.3904_3917del: p. Val1302Glyfs*60	0	0
40	IABB4	15	101113962	T	-	LINS1 (MRT27; MIM 614340; Geisinger AR)	frameshift del	NM_001040616.3: exon5: c.1116delA: p. Glu372Aspfs*9	0	0
41	SMPA76	16	716004	C	T	<b>WDR90</b>	Nonsynonymous	NM_145294.4: exon36: c.4489C>T: p. Arg1497Trp	3.72E-06	8.04E-06



Biallelic variants for autism....

42	IABB14	17	3392637	G	T	ASPA (Canavan disease; MIM 271900)	Splicing	NM_001128085: exon5: c.634+1G>T	1.06E-05	3.28E-05
43	SA2	19	14024452	G	T	CC2D1A (MRT3; MIM 608443; SFARI score 2; Geisinger AR)	Splicing	NM_017721: exon6: c.748+1G>T	0	0
44	IABB16	19	50321659	G	A	MED25 (BVFYS; MIM 616449)	Nonsynonymous	NM_030973.3: exon1: c.61G>A: p. Val21Met	0	0
45	SA11	19	58265432	C	-	<b>ZNF766</b>	Frameshift del	NM_173632.4:c.934delC: p.Arg312Glufs*80	3.266E-5	1.55E-5
46	IABB16	20	2847201	C	A	<b>VPS16</b> (Dystonia (AD) MIM 619291)	Nonsynonymous	NM_080413.3: exon20: c.2069C>A: p. Ala690Glu	1.99E-05	6.53E-05
47	IABB16	20	16360737	A	G	KIF16B (PMID 29736960)	Nonsynonymous	NM_001199865.2: exon19: c. T1910T>C: p. Val637Ala	0	0
48	IABB5	20	44578999	C	T	ZNF335 Hu et al, 2019; MCPH10; MIM 615095; Geisinger Tier 4)	Nonsynonymous	NM_022095.3: exon22: c.3346G>A: p. Gly1116Arg	1.26E-5	0
49	IABB11	22	40803252	G	C	<b>SGSM3</b> (SFARI score 2; Geisinger Tier 4)	Nonsynonymous	NM_001350039.2:c.1288G>C:p.Glu430Gln	1.99E-5	1.63E-4

698 # SpliceAI predicts the generation of a splice donor site.

699

700 **Table 3: De novo variants.** Genes previously reported as pathogenic for ASD/ID or other disorder are indicated, with annotation  
701 using (in order of priority): OMIM: <https://omim.org/>; SFARI ASD genes <https://gene.sfari.org/>; DDD gene2phenotype genes:  
702 <https://www.ebi.ac.uk/gene2phenotype/>; Geisinger developmental brain disorder gene database: <https://dbd.geisingeradmi.org/>;  
703 NPdenovo: <http://www.wzgenomics.cn/NPdenovo/>; Gene4denovo: <http://www.genemed.tech/gene4denovo/search>. Genes  
704 previously unreported for ASD or ID are in bold type. Control population frequencies shown are from gnomAD (all, and for South  
705 Asian sub-population). Allele frequencies are from gnomAD v2.1.1 (www. <https://gnomad.broadinstitute.org/>; accessed June 2022).  
706 All variants were validated by IGV (Integrated Genomics Viewer; Broad Institute) and by Sanger sequencing. Validations are shown in  
707 Supplementary Materials.

Biallelic variants for autism....

Variant	Family	Chr	Coordinates (hg19)	Ref.	Alt.	Gene (previously reported)	Variant Type	cDNA/Amino Acid Change	gnomAD All Freq.	gnomAD S. Asian Freq.
1	RQPA20	1	28919246	G	A	<b>RAB42</b>	nonsynonymous	NM_001193532.3: exon1: c. 223G>A: p. Glu75Lys	0	0
2	RQPA20	1	112031311	A	-	<b>TMIGD3</b>	frameshift del	NM_001302680.2: exon2: c.286delT: p. Trp96Glyfs*36	0	0
3	RQPA20	1	150483966	G	T	<b>ECM1</b> (DDD2P: lipoid proteinosis, AR)	Stopgain	NM_001202858.2: exon7: c.823G>T: p. Glu275*	7.96E-06	6.53E-05
4	RQPA20	1	160722912	C	A	<b>SLAMF7</b>	Stopgain	NM_001282589.2: exon5:c.560C>A: p. Ser187*	0	0
5	IAU29	2	1946866	C	-	MYT1L (MRD39: MIM 616521; SFARI score 1; MYT1L)	frameshift del	NM_001303052.2: exon9: c.394delG: p. Glu132Argfs*42	0	0
6	SMPA53	2	166166958	C	T	SCN2A (DEE11: MIM 6137219; SFARI score 1; Geisinger Tier 1)	Stopgain	NM_001040143.2: exon6:c.823C>T: p. Arg275*	3.98E-06	4.62E-05
7	SMPA38	2	166201156	C	A	SCN2A (DEE11: MIM 6137219; SFARI score 1; Geisinger Tier 1)	Nonsynonymous	NM_001040143.2:exon15:c.2654C>A:p.Thr885Asn	0	0
8	IAU66	2	232320177	C	-	<b>NCL</b>	frameshift del	NM_005381: exon13: c.1991delG: p. Gly664Glyfs*70	0	0
9	SA1	3	38645393	A	T	<b>SCN5A (BRGDA1: MIM 601144)</b>	Nonsynonymous	NM_198056.3:exon12:c.1700T>A: p. Leu567Gln	8.031E-6	0
10	SMPA75	5	137680632	-	T	<b>FAM53C</b>	frameshift ins	NM_001135647.2: exon4: c.256dupT: p. Ser86Phefs*14	0	0
11	SMPA75	6	47646871	G	A	<b>ADGRF2</b>	Splicing	NM_153839.7: exon5: c.267+1G>A	4.01E-06	3.27E-05

Biallelic variants for autism....

12	Autism10	6	87969507-87969508	AG	-	ZNF292 (MRD64: MIM 619188; SFARI score 1; Geisinger Tier 1)	frameshift del	NM_015021.3: exon8: c.6159_6160del: p. Glu2054Lysfs*14	0	0
13	IAU65	6	87969506-87969507	AG	-	ZNF292 (MRD64: MIM 619188; SFARI score 1; Geisinger Tier 1)	frameshift del	NM_015021.3: exon8: c.6159_6160del: p. Glu2054Lysfs*14	0	0
14	RQPA20	11	46389550	A	C	<b>DGKZ</b>	Splicing	NM_201533: exon4: c.379-2A>C	0	0
15	Autism9	12	52188238	G	A	SCN8A (DEE13: MIM 614558; SFARI score 1)	Nonsynonymous	NM_014191.4:c.4608G>A: p.Met153Ile	0	0
16	SMPA73	12	89998008	G	C	ATP2B1 (MRD66: MIM 619910; SFARI score 3S)	Stopgain	NM_001001323.2: exon15:c.2558C>G: p. Ser853*	0	0
17	RQPA20	16	89006655	G	A	<b>LOC100129697/CBF A2T3</b>	Nonsynonymous	NM_001290330.2: exon1: c.53G>A: p. Arg18Lys	0	0
18	SMPA75	19	7734220-7734221	CT	-	<b>RETN</b>	frameshift del	NM_001193374.1: exon2: c.8_9del: p. Cys5Serfs*13	4.37E-05	3.27E-04
19	RQPA20	22	20049060	C	G	<b>TANGO2 (Geisinger AR)</b>	Stop gain	NM_152906.7:exon7:c.459C>G: p.Tyr153*	0	0
20	RQPA20	22	22051034	A	G	<b>PPIL2</b>	Splicing	NM_148175: exon21: c.1570-2A>G	0	0

708

709 **Table 4: X-linked variants.** Genes previously reported as pathogenic for ASD/ID or other disorder are indicated, with annotation  
710 using (in order of priority): OMIM: <https://omim.org/>; SFARI ASD genes <https://gene.sfari.org/>; DDD gene2phenotype genes:  
711 <https://www.ebi.ac.uk/gene2phenotype/>; Geisinger developmental brain disorder gene database: <https://dbd.geisingeradmi.org/>;  
712 NPdenovo: <http://www.wzgenomics.cn/NPdenovo/>; Gene4denovo: <http://www.genemed.tech/gene4denovo/search>. Genes

Biallelic variants for autism....

713 previously unreported for ASD or ID are in bold type. Control population frequencies shown are from gnomAD (all, and for South  
 714 Asian sub-population). Allele frequencies are from gnomAD v2.1.1 (www. <https://gnomad.broadinstitute.org/>; accessed June 2022).  
 715 All variants were validated by IGV (Integrated Genomics Viewer; Broad Institute) and by Sanger sequencing. Validations are shown in  
 716 Supplementary Materials.

Variant	Family	Mode of Inheritance	Coordinates (hg19)	Ref	Alt	Gene (previous reports)	Variant Type	cDNA/Amino Acid Change	gnomAD All Freq.	gnomAD S. Asian Freq.
1	SMPA3	Recessive	30236780	C	-	<b>MAGEB2</b>	frameshift del	NM_002364.4:c.83delC:p.Pro28Leufs*84	0	0
2	IAU66	Recessive	48672948	A	G	<b>HDAC6</b>	Nonsynonymous	NM_006044.4:c.908A>G: p.Tyr303Cys	0	0
3	IAU69	Recessive	55779942	T	C	<b>RRAGB</b>	Nonsynonymous	NM_006064.4: exon7: c.730T>C: p. Phe244Leu	5.49E-06	1.23E-05
4	IAU45	Recessive	64947718	C	A	<b>MSN</b>	Nonsynonymous	NM_002444.3: exon3: c.139C>A: p. Leu47Met	0	0
5	SMPA15	Recessive	105193588	C	T	<b>NRK</b>	Stopgain	NM_198465.4: exon27: c.4375C>T: p. Gln1459*	0	0
6	IAU47	Recessive	107170098	A	G	MID2 (MRX101; MIM 300928)	nonsynonymous	NM_012216.4:c.2003A>G:p.Tyr668Cys	0	0
7	IAU24	Recessive	129290446	C	T	AIFM1 (Cowchock syndr.; MIM 310490)	nonsynonymous	NM_001130847.4: exon2: c. 238G>A: p. Ala80Thr	0	0

Biallelic variants for autism....

8	IAU51	Recessive	140994661	-	A	<b>MAGEC1</b>	frameshift ins	NM_005462.3:c.1471_1472insA; p.Leu491Tyrf*10	4.37E-05	0
9	IABB8	Recessive	152106616	A	G	<b>ZNF185</b>	Splicing	NM_001178110: exon13: c.942-2A>G	0	0
10	SA1	De Novo	15677205	T	A	<b>CLTRN (TMEM27)</b>	nonsynonymous <sup>&amp;</sup>	NM_020665.3:exon3:c.137A>T:p.Glu4 6Val	0	0
11	SMPA71	De Novo	62926209	G	A	ARHGEF9 (DEE8; MIM 300607; SFARI score 1S; Geisinger Tier1)	nonsynonymous	NM_015185.3: exon3:c.310C>T: :p.Arg104Trp	0	0
12	SMPA84	De Novo	100507601	A	C	DRP2 (CMTX1 MIM 302800; PMID 26227883)	nonsynonymous	NM_001171184.2: exon15: c. 1639A>C: p. Ser547Arg	0	0
13	IAU54	De Novo	153296081	-	T	MECP2 (RTT; MIM 312750; SFARI score 1; Geisinger Tier1)	frameshift ins	NM_001110792.2:exon3:c.1234dup:p. Thr412Asnfs*5	0	0
14	SMPA78	De Novo	153296516	G	A	MECP2 (RTT; MIM 312750; SFARI score 1' Geisinger Tier1)	Stopgain	NM_001110792.2:exon3:c.799C>T:p. Arg267*	0	0

717 <sup>&</sup>MutationTaster predicts splice donor created

Biallelic variants for autism....

718 **Table 5: CNV summary:** validated biallelic loss CNVs called by CNVpartition or ChAS. Biallelic losses called from microarray data by  
 719 PennCNV and from WES data by CLAMMS (81)) did not validate using IGV, and hence are not included. Comparison with control  
 720 population CNVs used the Database of Genomic Variants (DGV) Gold, accessed through the Decipher genomic browser  
 721 ([www.deciphergenomics.org](http://www.deciphergenomics.org)), also through gnomAD. Coordinates given using hg19.

Family	Mode of Inheritance	(hg19)	Cytoband	Size (Kb)	CN	CNV confidence	Genes	FREQ IN DGV GOLD STANDARD, gnomAD, or rare?	IGV	PCR
SMPA4	Recessive	14:24,454,924-24,464,325	14q11.2	9.402	0	345.9659	DHRS4 exon 8; DHRS4L2 exons 1-4	Partial overlap with gssvL33876 FREQ 0.0029	Y	Y
SMPA4	Recessive	20: 43836785-43836964	20q13.12	0.18	0	228.5597	SEMG1 exon 2, 180bp, 60 amino acids	Partial overlap with gssvL72784 FREQ 0.0038	Y	Y
SMPA8	Recessive	2:196,799,394-196,801,362	2q32.3	1.969	0	139.6294	DNAH7 exon 20-21	NONE	Y	Y
SMPA3	Recessive	5:140,224,038-140,242,319	5q31.3	18.282	0	1417.866	PCDHA9, PCDHA10 (SFARI score 2)	Also Hom in mother	Y	Y
IAH2	Recessive	5:140,224,038-140,242,319	5q31.3	18.282	0	1417.866	PCDHA9, PCDHA10 (SFARI score 2)	Also Hom in father	Y	Y
IAU79	Recessive	20:1,559,259-1,559,330	20p13	0.072	0	171.6751	SIRPB1 exon 2	Partial OVERLAP WITH COMMON CNV (0.0894)	Y	Y
IABB2	Recessive	17:3513856- 3514054	17p13.2	0.198	0	318.3258	SHPK exon 7	Partial OVERLAP WITH 80Kb gssvL47583 (0.00274)	Y	Y
IABB14	Recessive	15:85186877-85186894	15q25.2	0.018	0	55.68398	WDR73 exon 8 <sup>s</sup>	rs760394400; gnomAD MAF 0.1672	Y	Y
IABB14	Recessive	19:41356319-41386033	19q13.2	29.714	0	579.0146	CYP2A7 6 exons	gssvL58578 0.002 Plus gssvL58575 0.0017	Y	Y

Biallelic variants for autism....

IABB14	Recessive	19: 51330951-51331063	19q13.33	0.112	0	579.0146	KLK15 exon 2	Overlap with gssvL59230 0.02	Y	Y
SMPA42	X-linked	X:47912041-47970683	Xp11.23	58.643	0	1665.299	ZNF630; SSX6	Deletions in ZNF630 do not segregate with ID; PMID 20186789	Y	
SMPA9	X-linked	X:47917867-47970683	Xp11.23	52.817	0	1558.271	ZNF630; SSX6	Ditto	Y	

722 \$ see Riazuddin et al, 2017; PMID\_30171209)

Biallelic variants for autism....

723 **Figure Legends**

724 **Figure 1: Variant prioritization methods where variants that pass GATK best practices would**  
725 **be filtered for MAF less than or equal to  $10^{-4}$  and then categorized into recessive or**  
726 **homozygous variants.** Variants are then prioritized based on assessment of potential damage  
727 to the protein, and then filtered based on scoring algorithms to predict pathogenicity.

728

729 **Figure 2: Violin plots comparing consanguinity coefficient  $F_{roh}$ , for A:** different categories of  
730 variant identified: All biallelic variants (N=27 observations), variants in known AR ID and/or ASD  
731 genes (N=10 observations), variants in novel candidate genes (N=17 observations), all X-linked  
732 (XL) variants plus *de novo* autosomal dominant (AD) variants (N=18 observations), variants in  
733 known XL and AD genes (N=11 observations), and variants in novel candidate XL and AD genes  
734 (N=7 observations). Unpaired *t* test (2-tailed) for comparison of means showed comparison for  
735 i) all biallelic versus all *de novo* autosomal plus X-linked to be extremely significant ( $p < 0.0001$ ,  
736  $t = 5.8309$ , d.f.=51), ii) known AR versus AD ID and/or ASD genes to be strongly significant  
737 ( $p = 0.0045$ ,  $t = 3.1642$ , d.f.=22), iii) novel candidate AR versus AD genes to be strongly significant  
738 ( $p < 0.0001$ ,  $t = 5.4795$ , d.f.=26). No significant difference in mean  $F_{roh}$  was seen for comparisons  
739 between known and novel candidate AR genes, or between known and novel AD plus XL genes;  
740 **B:** different cohorts, categorized by last name of principal investigator for each collection (Agha,  
741 N=3, Ansar, N=52, Heidari, N=2, Al Ayadhi, N=13, Bozorgmehr, N=10, Sasanfar, N=24  
742 observations). While  $F_{roh}$  distribution was similar for most cohorts, the Iranian cohort from  
743 Sasanfar had a significantly lower mean than most other cohorts; **C:** grouped by country of



## Biallelic variants for autism....

744 origin (Pakistan, N=55, Iran, N= 36, Saudi Arabia=13 observations). Comparison of mean  $F_{roh}$   
745 was non-significant for Pakistan versus Iran and versus Saudi Arabia, but significant for Iran  
746 versus Saudi Arabia, but non-significant after correction for multiple testing ( $p=0.0206$ ,  $t=2.396$ ,  
747  $d.f.=36$ ). Plots were prepared using R software using ggplot2, and show mean, standard  
748 deviation, and outliers marked by “X”.

Microarray genotyping proband (Illumina CoreExome or Affymetrix CytoScanHD)

PCR screen for Fra(X)- exclude

Consanguinity analysis: PLINK, RoH

CNV: 1. hom exonic del  
2. Phenocopies

medRxiv preprint doi: <https://doi.org/10.1101/2021.12.24.21268340>; this version posted October 8, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

WES: Illumina NovaSeq/Agilent SureSelect V5; Filter variants as per GATK v4 Best Practices

Heterozygous  
(Variants must pass all filtering criteria)

Homozygous  
(Variants must pass 4/7 filtering criteria)

Stop-gain variants

Indels

Splice variants

Non-synonymous variants

Filtered Polyphen2 > 0.8, Mutation Taster > 0.8, CADD > 20

Frameshift > 20 reads and on +/- strand reads



Stop Filters + FATHMM > 0.8, dbSNV > 0.8, SpliceAI > 0.5

Stop Filters, FATHMM > 0.8, Mutation Assessor > 0.8, M-CAP > 0.025


Validation/segregation on IGV and Sanger sequencing

Cross reference datasets: controls (gnomAD) and disease (ClinVar, MSSNG, DECIPHER, SFARI, ASC, AutismKB, de Rubeis et al, DGV); neuroanatomical transcription, electrophysiological phenotypes.

**A**



**B**



**C**

